The purpose of this study is to evaluate the efficacy and safety of NicVAX co-administered with varenicline as an aid in smoking cessation over a one-year period in smokers who want to quit smoking.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
558
NicVAX vaccine given 6 times over 6 months
Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Slotervaart Hospital/ Smoking Cessation Clinic
Amsterdam, North Holland, Netherlands
Long term abstinence
Time frame: one year
Safety, immunogenicity
Time frame: continuous assessment throughout the one year study duration
Abstinence
Time frame: continuous assessment throughout the one year study duration
Lapse and relapse rate
Time frame: continuous assessment throughout the one year study duration
Withdrawal symptoms
Time frame: continuous assessment throughout the one year study duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.